Long-term Anticoagulation for Venous Thromboembolism: Duration of Treatment and Management of Warfarin Therapy

2010 ◽  
Vol 31 (4) ◽  
pp. 719-730 ◽  
Author(s):  
Clive Kearon
Keyword(s):  
Venous Thromboembolism ◽  
Warfarin Therapy ◽  
Duration Of Treatment

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

2003 ◽  
Vol 348 (15) ◽  
pp. 1425-1434 ◽  
Author(s):  
Paul M Ridker ◽  
Samuel Z. Goldhaber ◽  
Ellie Danielson ◽  
Yves Rosenberg ◽  
Charles S. Eby ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Warfarin Therapy ◽  
Low Intensity ◽  
Recurrent Venous Thromboembolism

Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism

2004 ◽  
Vol 59 (2) ◽  
pp. 78-80
Author(s):  
Clive Kearon ◽  
Jeffrey S. Ginsberg ◽  
Michael J. Kovacs ◽  
David R. Anderson ◽  
Philip Wells ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Warfarin Therapy ◽  
Low Intensity ◽  
Recurrent Venous Thromboembolism

scholarly journals A Review of Warfarin Dosing and Monitoring

2018 ◽  
Vol 13 (1) ◽  
pp. 40-43 ◽  
Author(s):  
Khan Md Arif ◽  
Mohammad Ashiqur Rahman
Keyword(s):  
Venous Thromboembolism ◽  
Heart Valves ◽  
Warfarin Therapy ◽  
Thrombus Formation ◽  
Therapeutic Index ◽  
International Normalized Ratio ◽  
Major Surgery ◽  
Clotting Factors ◽  
Duration Of Treatment ◽  
Oral Anticoagulant Treatment

The anticoagulant drug warfarin is a vitamin K antagonist, coumarin derivative which inhibits the synthesis of clotting factors II, VII, IX, and X, as well as the naturally occurring endogenous anticoagulant proteins C and S. Warfarin is still considered the mainstay of oral anticoagulant treatment, it is a difficult drug to manage due to its narrow therapeutic index. An inappropriate management of patients can lead to subtherapeutic or supratherapeutic levels, increasing the risk of thromboembolic episodes or hemorrhagic episodes, respectively. Common indications for the use of warfarin include stroke prevention in atrial fibrillation, preventing thrombus formation in patients with heart valves and treatment of venous thromboembolism. When warfarin therapy is initiated for venous thromboembolism, it should be given the first day, along with a heparin product or fondaparinux. The heparin product or fondaparinux should be continued for at least five days and until the patient's international normalized ratio is at least 2.0 for two consecutive days. The international normalized ratio goal and duration of treatment with warfarin vary depending on indication and risk. Warfarin therapy should be stopped five days before major surgery and restarted 12 to 24 hours postoperatively. Bridging with low-molecular-weight heparin or other agents is based on balancing the risk of throm boembolism with the risk of bleeding.Faridpur Med. Coll. J. Jan 2018;13(1): 40-43

Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism

2003 ◽  
Vol 349 (7) ◽  
pp. 631-639 ◽  
Author(s):  
Clive Kearon ◽  
Jeffrey S. Ginsberg ◽  
Michael J. Kovacs ◽  
David R. Anderson ◽  
Philip Wells ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Warfarin Therapy ◽  
Low Intensity ◽  
Recurrent Venous Thromboembolism
Sign in / Sign up

Export Citation Format

Share Document